Company intelligence / Profile preview

Megadalton Solutions

Bloomington, Indiana, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Megadalton Solutions developed a platform for high-precision mass characterization of large molecules, including AAVs, VLPs, and nanoparticles. Its Charge Detection Mass Spectrometry (CDMS) technology addresses the analytical challenge of quantifying intact gene therapy vectors, including empty and full capsid ratios. As of acquisition, their platform was generating limited service revenue in research/commercial partnerships but not yet a commercialized product for broad sale[2][4].

Therapeutic areas: OtherRare Diseases
Modalities: Gene therapyBiologicNanoparticle
Industry: Drug Discovery Services

Partnerships

WatersSartorius (via Waters' partnership after acquisition)

Beyond the preview

Go deeper on Megadalton Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Megadalton Solutions.

Explore the full profile